Lumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%
MT Newswires Live
Jul 21
Lumos Diagnostics (ASX:LDX) is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.
The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.
FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.
Shares fell 3% in midday trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.